The present disclosure relates to the field of biological-sample testing. Disclosed is a biological-sample rapid testing device, which is used for conveniently and accurately injecting samples into reaction tanks. The biological-sample rapid testing device comprises a cover, a cylinder and a biological-sample accommodating body, wherein the cylinder comprises a mounting cavity and a plurality of reaction tanks, each reaction tank being in communication with the mounting cavity; the cover is detachably mounted at a top opening of the mounting cavity; and the biological-sample accommodating body is removably located inside the mounting cavity and comprises a sample tank, a liquid discharge pipe and an exhaust flow channel, one end of the liquid discharge pipe being in communication with the sample tank, the other end of the liquid discharge pipe being in communication with the reaction tanks, one end of the exhaust flow channel being in communication with the reaction tanks, and the other end of the exhaust flow channel extending to the top face of the biological-sample accommodating body. By means of the solution, a biological sample can be injected into a reaction tank without requiring other containers, biological samples can be injected into a plurality of reaction tanks in one step by means of flow splitting, the injection quantity is accurate and controllable, and the injection efficiency is high.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
Provided are a recombinant respiratory syncytial virus (RSV) fusion (F) protein, and a fusion protein, vaccine, immunogenic composition, kit and pharmaceutical composition comprising same. Further provided is a use of the recombinant RSV F protein, fusion protein, vaccine, immunogenic composition, kit and pharmaceutical composition in preventing and/or treating RSV infection or diseases and/or symptoms caused by RSV infection.
A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12N 15/45 - Paramyxoviridae, p. ex. virus de la rougeole, virus des oreillons, virus de la maladie de Newcastle, virus de la maladie de Carré, virus de la peste bovine, virus respiratoires syncytiaux
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
3.
HIGH-THROUGHPUT FULL-AUTOMATIC NUCLEIC ACID DETECTION INSTRUMENT AND METHOD
A high-throughput full-automatic nucleic acid detection instrument and method. The high-throughput full-automatic nucleic acid detection instrument comprises: a base; a transfer module, which is arranged on the base; a pipetting module, which is used for adding detection samples into a plurality of plate holes in a nucleic acid extraction plate on the transfer module; a nucleic acid extraction module, which comprises a plurality of magnetic head assemblies, wherein the magnetic head assembly comprises a driving device, a sleeve, a magnetic rod and magnetic beads, the driving device being used for driving the magnetic rod to be extended into or withdrawn from the sleeve, the magnetic rod being used for attracting or releasing the magnetic beads, when the magnetic rod is extended into the sleeve, the magnetic beads being attracted to an outer wall of the sleeve, and the magnetic beads being transferred between the plate holes along with the sleeve, and when the magnetic rod is withdrawn from the sleeve, the magnetic beads with nucleic acids adsorbed being released in the plate holes, so as to transfer the nucleic acids; and a PCR detection module, which is used for performing PCR detection on a PCR detection plate added with the nucleic acids. Regional division and pressure control are performed on modules on the basis of a nucleic acid detection process, and contamination leakage of a PCR detection region is prevented and controlled by means of a closable chamber door and a negative pressure system.
An immune-enhancing aluminum emulsion, and a preparation method therefor and a use thereof. Specifically provided are an oil-in-water emulsion containing an inorganic salt and a preparation method for the oil-in-water emulsion. Also provided are a vaccine adjuvant comprising the oil-in-water emulsion, a vaccine composition and a pharmaceutical composition. Also provided is a use of the oil-in-water emulsion as a vaccine adjuvant.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
5.
CITRULLINATED SETDB1 POLYPEPTIDE AND USE THEREOF IN DIAGNOSIS OF RHEUMATOID ARTHRITIS
A method for diagnosing rheumatoid arthritis on the basis of the level of an anti-citrullinated SETDB1 antibody, and a kit for use in the method. Provided are a polypeptide for the above-mentioned diagnosis of the level of an anti-citrullinated SETDB1 antibody, and the use thereof in the diagnosis of rheumatoid arthritis.
C07K 4/12 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'animauxPeptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'humains
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
6.
FUSION PROTEIN OF GE AND GI OF VARICELLA-ZOSTER VIRUS AND USE
The present invention provides fusion proteins of gE and gI (or variants thereof) that can be used for preventing or treating varicella-zoster virus infection, and use of such fusion proteins (or the variants thereof).
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
7.
ANTIGEN FOR 2019 NOVEL CORONAVIRUS AND DETECTION USE THEREOF
Provided are a method for assaying a specific IgM antibody and a total antibody for the 2019 novel coronavirus (2019-nCOV), a method for determining whether subjects are infected with 2019-nCOV, and a virus antigen and a kit for carrying out the above-mentioned detection.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
8.
POLYPEPTIDE ENCODED BY EB VIRUS BNLF2B GENE AND USE THEREOF IN DETECTION
Provided are a method for diagnosing nasopharyngeal carcinoma on the basis of the anti-EB virus (EBV) antibody level and a kit used for the method. Also provided are a polypeptide encoded by a BNLF2b gene in EB virus used for the above-mentioned diagnosis and the use thereof for diagnosing nasopharyngeal carcinoma.
The present invention belongs to the field of immunobiology, and relates to an epitope polypeptide, such as a general affinity epitope polypeptide for human rhinovirus, and the use thereof. The present invention further relates to an antibody capable of binding to the epitope polypeptide and the use thereof. The present invention further relates to the use of the affinity epitope polypeptide or the antibody in the preparation of drugs or in methods for treating and/or preventing and/or diagnosing human rhinovirus and/or identifying a titer of human rhinovirus and/or identifying a titer of a neutralizing antibody of human rhinovirus. The affinity epitope polypeptide and the antibody can be used in drugs or methods for treating and/or preventing and/or diagnosing human rhinovirus and/or identifying a titer of human rhinovirus and/or identifying a titer of a neutralizing antibody of human rhinovirus.
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
10.
ANTIGEN FOR 2019 NOVEL CORONAVIRUS AND DETECTION USE THEREOF
Provided are a method for assaying a specific IgM antibody and a total antibody for the 2019 novel coronavirus (2019-nCOV), a method for determining whether subjects are infected with 2019-nCOV, and a virus antigen and a kit for carrying out the above-mentioned detection.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/558 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène
C12N 15/65 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression utilisant des marqueurs
C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
11.
ORF7 deficient varicella virus, vaccine comprising the virus and use thereof
The present invention relates to a detection mechanism for polymerase chain reaction and a polymerase chain reaction device, wherein the detection mechanism comprises at least one excitation module group, each of the excitation module groups comprising two excitation modules for providing excitation light with two wavelengths; an excitation optical fiber, connected to the excitation modules, the excitation optical fiber transmitting the excitation light to at least one reaction tube, each of the reaction tubes receiving excitation light with two wavelengths; a receiving optical fiber, for collecting and transmitting a fluorescent signal from the reaction tube; at least one receiving module group, connected to the receiving optical fiber, each of the receiving module groups comprising two receiving modules, to respectively receive the fluorescent signal of two wavelengths from the same said reaction tube, and convert the fluorescent signal into an electrical signal for output; the detection mechanism is configured to detect the reaction tube in a time division manner, and multiplex the receiving module group to obtain an output result.
Disclosed are a system and a method for detecting convective PCR amplification. The system comprises: a microfluidic chip, comprising a storage structure, a convective PCR tube, an FTA film and a waste liquid receiving structure, wherein a first end of the convective PCR tube is in communication with a storage cavity of the storage structure, a second end of the convective PCR tube is in communication with a waste liquid cavity of the waste liquid receiving structure, and the FTA film is arranged in the convective PCR tube so as to filter a solution flowing from the first end of the convective PCR tube to the second end of same, and is capable of adsorbing nucleic acids in the solution onto the surface of the FTA film; a flow control module, used for making a solution in the storage cavity flow into the convective PCR tube and for making same be filtered via the FTA film, and then enter the waste liquid cavity; a heating module, used for heating materials in the convective PCR tube; and an optical detection module, used for the fluorescence detection of materials in the convective PCR tube.
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
14.
ORF7 deficient varicella virus, vaccine comprising the virus and use thereof
Disclosed are a method for diagnosing whether a subject is suffering from active tuberculosis, a method for judging the therapeutic effect of a therapy on active tuberculosis, a method for screening a candidate drug capable of treating active tuberculosis, and a kit comprising a specific stimulating agent and a reagent for detecting IL-6 levels. The methods and kit are used in the fields of molecular biology, immunology and disease diagnosis.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
16.
DETECTION MECHANISM FOR POLYMERASE CHAIN REACTION AND POLYMERASE CHAIN REACTION DEVICE
A detection mechanism (3) for a polymerase chain reaction and a polymerase chain reaction device. The detection mechanism (3) comprises: at least one exciting module group, each exciting module group comprising two exciting modules (31) and being capable of providing exciting light having two different wavelengths; an exciting optical fiber (32), connected to the exciting module group, the exciting optical fiber (32) being capable of transmitting the exciting light to at least one reaction test tube (5), and each reaction test tube (5) receiving exciting light having two different wavelengths; a receiving optical fiber (33), capable of collecting and transmitting a fluorescence signal of the reaction test tube (5); and at least one receiving module group, connected to the receiving optical fiber (33), each receiving module group comprising two receiving modules (34) so as to receive fluorescence signals having two different wavelengths from the same reaction test tube (5) respectively, and to convert the fluorescence signals into electric signals to be output. The detection mechanism (3) detects the reaction test tube (5) in different periods, and reuses the receiving modules to obtain an output result.
Provided in the present invention is a chimeric recombinant antigen and the use thereof in diagnosing Mycobacterium tuberculosis infections. The chimeric recombinant antigen comprises 3 antigen regions derived from Mycobacterium tuberculosis-specific proteins, Rv3875, Rv3874 and TB7.7, respectively, and can be used to detect specific T cell-immune response in vitro.
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
The RNAi target sequences, which could be used for treating AIDS through targeting HIV. Based on the target sequences, recombinant expression vectors, packaging vectors and cells were constructed, which express siRNA and/or miRNA and/or ribozyme and/or antisense oligonucleotide for targeting HIV. And the applications of said recombinant expression vectors, packaging vectors and cells in preparing medicament for treating AIDS.
The present invention provides monoclonal antibodies that bind specifically to H5 subtype avian influenza virus hemagglutinin (HA) proteins, and can block the binding activity of at least 50% of the known monoclonal antibodies to the H5 subtype avian influenza virus hemagglutinin (HA) protein. The monoclonal antibodies can be used for the detection, diagnosis, prevention, and treatment of avian influenza viruses, especially the H5 subtype of avian influenza viruses. The present invention also provides the related hybridoma cell lines, isolated nucleic acid molecules and short peptides, as well as medical composition and medical diagnostic equipment and kit containing the monoclonal antibody.
The present invention provides humanized antibodies that specifically bind to the hemagglutinin of avian influenza virus subtype H5. Such humanized antibodies are useful in the prevention and treatment of the diseases caused by avian influenza virus, particularly the avian influenza subtype H5. Also provided herein are the related amino acid sequences, and pharmaceutical compositions containing the humanized antibodies.
Provided are truncated L1 proteins of human papillomavirus 11, virus-like particles made of them, vaccines comprising the virus-like particles and uses thereof for preventing condylomata acuminata or HPV infections.
Provided are truncated L1 proteins of human papillomavirus 6, virus-like particles made of them, vaccines comprising the virus-like particles and uses thereof for preventing condyloma acuminata or HPV infections.
Provided are truncated L1 proteins of human papillomavirus 16, virus-like particles made of them, vaccines comprising the virus-like particles and uses thereof for preventing cervical cancer.
Provided are truncated human papillomavirus type 18 L1 proteins and virus like particles assembled from the L1 proteins. Also provided are the vaccines comprising the virus like particles and the use of the vaccines in prevention of cervical carcinoma.
A method of jointly detecting HBV preS1 antigen and core antigen, test kit, solid substrate and virus lysis solution thereof. A double-antibody sandwich method is used to detect HBV preS1 antigen and core antigen.
G01N 33/576 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour l'hépatite
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
brevets
